Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flu Vaccine Efficacy Is Too Low To “Sell,” CDC Says; Firms Want More Demand

Executive Summary

More efficacious influenza vaccines must be developed in order to encourage use, Centers for Disease Control & Prevention Smallpox Preparedness & Response Activity Director Ray Strikas, MD, said

You may also be interested in...



Vaccine Market Transition: Flu Pandemic, Stockpile Plan May Drive Production

HHS is seeking to increase influenza vaccine production capacity through financial incentives in the form of higher governmental demand

Vaccine Market Transition: Flu Pandemic, Stockpile Plan May Drive Production

HHS is seeking to increase influenza vaccine production capacity through financial incentives in the form of higher governmental demand

Chiron To Distribute Fluvirin Directly To Providers For 2004-2005 Flu Season

Chiron plans to distribute its injectable influenza vaccine Fluvirin directly to some providers this year to increase its profit margins

Related Content

UsernamePublicRestriction

Register

PS043341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel